Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leu…

Recurrent T Acute Lymphoblastic LeukemiaRefractory T Acute Lymphoblastic LeukemiaRefractory T Lymphoblastic Lymphoma+1 more

SWOG Cancer Research NetworkNCT04315324